Percutaneous coronary intervention (PCI) with bare metal stent (BMS) in patients with renal insufficiency has shown unsatisfactory results. Indeed, drug-eluting stents (DES) might reduce the incidence of restenosis and therefore of target lesion revascularization procedures in these patients. We therefore designed a prospective, randomized, multicenter, not-sponsored study to directly compare the efficacy in the prevention of clinical restenosis of everolimus-eluting stent (Xience V) and bare-metal stent (Vision) (both 2nd-generation DES and BMS, respectively), both implanted in the same patient with multivessel disease and renal insufficiency in order to obviate for the multiple and unpredictable characteristics of this high-risk population.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
215
Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
European Hospital
Rome, Italy
Azienda Ospedaliera Istituti Ospitalieri di Verona
Verona, Italy
Ischemia-driven target vessel revascularization
Time frame: 9 months
Incidence of death and myocardial infarction
Time frame: in-hospital, 30 days, 9 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.